Organoids as a platform for personalized antisense oligonucleotide screening: Advancing precision medicine

Abstract

Organoid technology has transformed precision medicine by enabling patient-specific 3D models that replicate tissue complexity, facilitating high-throughput antisense oligonucleotide (ASO) therapeutic screening. Patient-derived organoids retain donor-specific genetic and phenotypic profiles, offering physiologically relevant platforms for modeling diseases, such as Duchenne muscular dystrophy (DMD). For example, DMD cardiac organoids rapidly identify dystrophin-restoring ASOs through a 6-week validation pipeline, overcoming limitations of 2D cultures by preserving multicellular interactions. Challenges include expanding tissue representation (e.g., skeletal muscle in DMD), enhancing ASO pharmacokinetic modeling in avascular organoids, and standardizing protocols to minimize variability. Future integration of vascularized or organ-on-chip models, multi-tissue assembloids, and artificial intelligence-driven screening could improve predictive accuracy. Chemically optimized ASOs with reduced off-target effects, combined with clustered regularly interspaced short palindromic repeats-based editing, may synergistically enhance therapeutic precision. As regulatory frameworks adapt to incorporate organoid-based validation, this technology accelerates personalized drug discovery for genetic disorders. Addressing present limitations through bioengineering and standardization will solidify organoids as critical tools for tailoring precision therapies to individual patient needs.

Keywords

Organoids / Antisense oligonucleotides / Personalized drug screening

Acknowledgments

None.

Funding

None.

Conflict of interest

The authors declare no conflicts of interest.

Author contributions

Conceptualization: All authors

Writing - original draft: Xufeng Wan

Writing - review & editing: Zongke Zhou, Duan Wang

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

[1] Wakefield L, Agarwal S, Tanner K. Preclinical models for drug discovery for metastatic disease. Cell. 2023; 186(8):1792-1813. doi: 10.1016/j.cell.2023.02.026

[2] Choudhury D, Ashok A, Naing MW. Commercialization of organoids. Trends Mol Med. 2020; 26(3):245-249. doi: 10.1016/j.molmed.2019.12.002

[3] Wang SQ, Chen JJ, Jiang Y, et al. Targeting GSTP1 as therapeutic strategy against lung adenocarcinoma stemness and resistance to tyrosine kinase inhibitors. Adv Sci (Weinh). 2023; 10(7):e2205262. doi: 10.1002/advs.202205262

[4] Prakash TP, Mullick AE, Lee RG, et al. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 2019; 47(12):6029-6044. doi: 10.1093/nar/gkz354

[5] Means JC, Martinez-Bengochea AL, Louiselle DA, et al. Rapid and scalable personalized ASO screening in patient-derived organoids. Nature. 2025; 638(8049):237-243. doi: 10.1038/s41586-024-08462-1

[6] Van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-945. doi: 10.1016/j.cell.2015.03.053

[7] Abutaleb ARA, McNally EM, Khan SS, Anderson AS, Carr JC, Wilcox JE. Myocarditis in duchenne muscular dystrophy after changing steroids. JAMA Cardiol. 2018; 3(10):1006-1010. doi: 10.1001/jamacardio.2018.2695

[8] Sidhaye J, Knoblich JA. Brain organoids: An ensemble of bioassays to investigate human neurodevelopment and disease. Cell Death Differ. 2021; 28(1):52-67. doi: 10.1038/s41418-020-0566-4

[9] Tang XY, Wu S, Wang D, et al. Human organoids in basic research and clinical applications. Signal Transduct Target Ther. 2022; 7(1):168. doi: 10.1038/s41392-022-01024-9

[10] Lindholm MW, Elmén J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012; 20(2):376-381. doi: 10.1038/mt.2011.260

[11] Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281-2308. doi: 10.1038/nprot.2013.143